I don't understand this. If it's the same drug for both trials, why would you partner for one and not the other. I doubt manufacture or end sales would be allocated to one condition and not the other.
Ann: Quarterly Appendix 4C and Activities Report, page-213
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.8¢ |
Change
-0.018(4.32%) |
Mkt cap ! $209.2M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 37.0¢ | $2.482M | 6.466M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 139732 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 119816 | 6 |
View Market Depth
| Last trade - 14.55pm 10/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |